TELA Bio, Inc.
Ovid Therapeutics Inc. (NASDAQ: OVID) operates as a commercial-stage medical technology company focused on soft-tissue reconstruction solutions. The company's website is located at www.ovidbio.com. Ovid develops and commercializes reinforced tissue matrices designed to optimize clinical outcomes by preserving and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TELA Bio, Inc. does
In the company’s own words
Ovid Therapeutics Inc. (NASDAQ: OVID) operates as a commercial-stage medical technology company focused on soft-tissue reconstruction solutions. The company's website is located at www.ovidbio.com. Ovid develops and commercializes reinforced tissue matrices designed to optimize clinical outcomes by preserving and restoring patients' own anatomy while minimizing long-term exposure to permanent synthetic materials.
The company's primary product portfolio consists of OviTex Reinforced Tissue Matrix and OviTex PRS Reinforced Tissue Matrix. OviTex addresses unmet needs in hernia repair and abdominal wall reconstruction by combining biologic matrices derived from ovine rumen with interwoven polymer fibers. The product is available in multiple configurations, including OviTex LPR for laparoscopic and robotic-assisted procedures and OviTex IHR specifically designed for inguinal hernia repairs. OviTex PRS serves plastic and reconstructive surgery applications, with three product configurations featuring two or three layers of ovine rumen tissue reinforced with permanent or resorbable polymers. The company also distributes complementary products including LIQUIFIX Hernia Mesh Fixation Devices through a distribution agreement with Advanced Medical Solutions Limited.
Ovid's revenue for the year ended December 31, 2025 was $80.3 million, with the vast majority generated from OviTex and OviTex PRS product sales in the United States, supplemented by European sales and other product revenues. The company operates primarily through a direct sales force concentrated in the U.S., with smaller sales representation in the United Kingdom and European Union, supplemented by independent contractors and distributors.
The company manufactures its products through an exclusive contract manufacturing relationship with Aroa Biosurgery Ltd., an FDA-registered and ISO 13485 compliant facility in Auckland, New Zealand. Ovid has established contracts with three national group purchasing organizations covering its primary products. The company estimates the annual U.S. total addressable market for OviTex products at approximately $1.8 billion and for OviTex PRS products at approximately $800 million. As of December 31, 2025, Ovid had accumulated losses of $397.6 million since inception.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1561921
- SIC
- 3841
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TELA Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TELA Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TELA Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TELA Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TELA Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”